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Abstract 
BACKGROUND: Skin, nervous tissue, dopamine and melanoma share a common neuroectodermal origin. 
Hence, processes that modulate nervous tissue formation, patient mental status, motor regulation of individuals, 
and skin cancerogenesis are inextricably linked. Psycho-neuro-endocrine oncology (or dermato-oncology), i.e. 
P.N.E.O., is a new model or trend in medicine and science presented for the first time in the world literature by us, 
that aims to examine the relationship between the mental state, the hormones and the malignant transformation. 
Schizophrenia and Parkinson’s disease are the two main patterns of disease where the main symptoms are 
related to dopamine levels in the human body. According to our analyses of the available literature, the amount of 
dopamine is related to the incidence of melanocytic or non-melanocytic cutaneous tumours in patients with central 
nervous system diseases and those affecting the motor function and coordination. Such patterns of interaction are 
extremely indicative of the elucidation of the ubiquitous hypothesis or statement: “My illness is on a mental basis, 
caused by stress ...” 
CASE PRESENTATION: We present a 44-year-old patient with untreated schizophrenia for approximately 25 
years, associated with advanced acral localised melanoma. Schizophrenia is generally associated with a higher 
level of dopamine, which is also a key precursor to melanin synthesis. After a careful analysis of all literature on 
melanoma in patients with 1) treated and untreated schizophrenia, 2) those with untreated and untreated forms of 
Parkinson’s disease, it would be logical to conclude that the high level of dopamine in the described patient 
groups is a risk factor for the development of melanoma. 
CONCLUSIONS: The possible mechanisms for the occurrence of malignant melanoma within the so-called 
psycho/neuro/endocrine oncology (P.N.E.O.), as well as the effective methods of prevention, are under 
discussion. 
 
 
 
 
 
Introduction 
 
Schizophrenia is a mental disorder affecting 
approximately 1% of the world population [1]. 
Standard therapy for patients with this disease is 
given with dopamine antagonists [2]. They are thought 
to have a protective effect on the development of 
malignant melanoma in patients with schizophrenia 
[3]. 
The statement of the anti-tumour effect of 
dopamine antagonists is based on the results of 
various studies which postulate that patients with 
Parkinson’s disease and dopamine agonist therapy 
have an increased incidence of malignant melanoma 
[4] [5]. 
 
 
Case report 
 
We present a 44-year old woman with head 
trauma suffered in childhood (falling from a bridge), 
soon afterwards diagnosed with paranoid 
schizophrenia. Patient complaints began 
approximately 26 years ago. Last, about 2 years ago, 
she received the antipsychotic drug Olanzapine 5mg 
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for 3-4 months. The patient is now receiving Biperiden 
Hydrochloride 2 mg (1-1-0) and Aripiprazole 
(antipsychotic) 15 mg (0-0-1) therapy. Her therapy is 
currently discontinued for schizophrenia. The patient 
reports the presence of a pigmented lesion on the 
medial surface of the left lower leg for approximately 
10 years. About 6 months ago she noticed the 
occurrence of nodules on the medial surface of her 
left lower leg, and subsequently, the pigment lesion 
progressively increased its size (Figure 1a).  
 
Figure 1: a) Primary cutaneous giant melanoma in a schizophrenic 
patient; b-f) Surgical excision of the primarius under general 
anaesthesia. A split skin meh graft was planned after 3 weeks 
 
Subjectively there is a complaint about 
itching. Approximately 4 months ago, the patient 
consulted a surgeon for that lesion and was referred 
for surgical removal of the formation. However, the 
patient refuses to undergo surgery and is 
conservatively treated with Povidone-iodine ointment 
and herbs. A subsequent significant increase in the 
size of the lesion was observed, which is the reason 
for hospitalisation. Dermatological examination 
revealed the presence of an exophytic, tumour-like 
formation with an erosive surface, in decay, releasing 
stenching smell, located on the medial surface of the 
left lower leg (Figure 1a).  
 
Figure 2: a-f) Inguinal lymph node dissection was carried out 
Additionally, the presence of enlarged lymph 
nodes in the left inguinal region (Figure 2a) was 
established. Radical removal of the primary tumour 
formation along with lymph dissection (inguinal and 
parailliacal) of the enlarged lymph nodes (Figure 1b-
1f, 2b-2f, 3a-3f iguinal/4a-4h parailliacal, Figure 5a-5c 
defect closure after the lymph node dissections44) 
was carried out.  
 
Figure 3: a-c) Arterial and venous vessels were not injured (Fig. 3a); 
the giant tumorous metastatic formation was completely removed 
(Fig. 3b, 3c) 
 
Histopathological evidence was for ulcerated 
nodular type of malignant melanoma, Breslow 
thickness of 18 mm, Clark IV-V, and 3 metastatic 
lymph nodes, two of them in the inguinal and 1 of 
them I the parailliacal area, staged as III D. The 
patient was redirected to the oncology department 
and a therapy with Interferon 3 x 3 Mio was planned. 
 
Figure 4: 3d-4h) The parailliacal lymph node dissection was 
performed parallel with the inguinal one (Fig. 4b). Several 
pigmented metastatic lymphatic nodes were removed additionally 
(Figs. 3e, 3f, 4a) 
 
 
Discussion 
 
Standard care treatment of schizophrenia as 
a chronic mental illness involves antipsychotic agents 
[2]. These drugs act as antagonists of the dopamine 
D2 receptors and serotonin 5-HT2A receptors, 
respectively, dopamine and serotonin [2]. There is an 
interesting hypothesis of a possible association 
between the intake of antipsychotics and the 
possibility of subsequent melanoma formation [3]. 
Already in 1982, an antitumor effect of dopamine 
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antagonists on the development of melanoma was 
discussed [3]. Melanoma culture research in mice 
then showed that the antidopaminergic agent 
(Pimozide) used had an inhibitory effect on mouse 
melanoma cells [3]. Similarly to other authors, we 
maintain that schizophrenic patients receiving anti-
dopamine therapy show a lower incidence of 
melanoma [6]. 
 
Figure 5: a-c) Defects closure with single cutaneous surgical 
stitches 
 
Under the effect of sunlight, mutations in 
melanoma cells occur, thus increasing the risk of 
melanoma in general [7]. Solar radiation induces 
mutations in the p53 genome regulator that is capable 
of inducing a cell block on the one hand (via certain 
inhibitory proteins such as p21, p27, p16) and, on the 
other, activating certain pro-apoptotic proteins such as 
Bax/Bak that in turn, cause cell death in tumor cells [8] 
[9]. The presence of mutations in p53 deactivates its 
functions and causes uncontrolled cellular 
proliferation, lack of possibility of the altered cells 
being eliminated by the activation of programmed cell 
death-apoptosis, ultimately resulting in the generation 
of the corresponding tumour branch [8] [9]. Whether 
this malignant branch will develop by impaired 
melanocyte or keratinocyte, at least hypothetically, 
should depend on the concentration or density of 
melanocytes localised on the basal level of the 
epidermis (as well as on the individual sensitivity of 
each patient that is multifactorial conditional). 
When melanin synthesis is enhanced or is 
enhancing (by external intervention such as dopamine 
agonist therapy for Parkinson’s disease or by internal 
intervention such as in untreated schizophrenia, for 
example), then mutations affect melanocytes (which 
density in the epidermis should have been increased) 
more often. Melanoma incidence in the two categories 
of patients described is as shown in other studies [4] 
[5]. Currently, there are no scientific studies to 
compare the incidence of melanoma and melanocyte 
density in patients with Parkinson’s disease and 
schizophrenia both across patients with Parkinson’s 
disease and healthy volunteers. 
From an anatomical point of view, albeit 
somewhat speculatively, the increased number of 
melanocytes could also be seen as a protective factor 
in the development of keratinocyte tumours. This is 
also anatomically determined by the fact that the 
network of the increased number of melanocytes, as 
well as the dendrites of the latter, cover the greater 
part of keratinocyte cells, thus “absorbing” the majority 
of the negative effect of solar radiation on “their 
account”. The more melanocytes in the basal layer of 
the epidermis, the higher the risk of melanoma 
development (when patients are exposed to UV 
radiation, and possibly have a genetic predisposition). 
In schizophrenic patients with increased 
levels of dopamine, it should be assumed that the 
number of melanocytes in the basal part of the 
epidermis is further increased. In the presence of 
intensive sunbathing in areas exposed to solar 
radiation, the cumulative risk of melanoma formation 
should further increase [10]. 
According to this hypothesis, antipsychotic 
drugs should reduce the number of melanocytes in 
the epidermis by reducing dopamine and hence the 
risk of melanoma formation. Indirectly, the risk of 
developing epithelial skin tumours such as basal cell 
and spinocellular carcinomas [11] should also 
increase. It is believed that the genes regulating skin 
pigmentation play a key role in the development of 
melanoma [12]. How, however, these genes involved 
in melanin synthesis affect the risk of melanoma 
development is still the subject of further studies [13]. 
It is believed that CDKN2A, MC1R, MITF genes are 
involved in melanocytes differentiation and 
development and that mutations in these genes are 
associated with the formation and progression of 
malignant melanoma, together with pigmentation [14]. 
Probably the common biochemical pathway of 
dopamine and melanin (with a common precursor, i.e. 
tyrosine) is the starting point that should be 
considered critically regarding the risk of melanoma 
formation in patients receiving dopamine preparations 
(antagonists or agonists) [15]. 
This is the place to mention an equally 
discussed topic about the risk of malignant melanoma 
in patients with Parkinson’s disease [16]. The therapy 
of patients with Parkinson’s disease includes 
dopamine agonists that increase dopamine levels 
and, hence, the risk of melanoma [4] [5] [17]. 
It is open and somewhat speculative question 
whether melanomas in patients with increased 
dopamine in the body develop on the basis of 1) 
increased melanocytes in the basal part of the 
epidermis, which determines completely randomly the 
possibility of mutations (due to the higher probability 
of occurrence following intense ultraviolet radiation), 
or this is due to 2) distorted processes within the 
melanogenesis itself (due to the presence of a certain 
product in abundance, which would lead to a possible 
blocking of some and activation of other pathogenic 
chains)? 
If we base our discussion on the described 
theory of psycho-neuro-endocrine oncology, it should 
be inevitably confirmed by studies in patients with 
Parkinson’s disease with elevated levels of melanin 
precursor dopamine [4]. Available data from a study in 
Parkinson’s patients show a 4.4 to the 7-fold higher 
risk of melanoma occurrence in these patients [4] [5]. 
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In conclusion, the risk of malignant melanoma 
development depends on some factors. We believe 
that in patients receiving dopamine antagonist’s 
therapy, the reduced dopamine level may reduce the 
potential for melanoma development, and the 
biomechanisms of this anti-tumour effect are 
determined by a genetic level. In support of this, there 
is evidence that dopamine agonists used to treat 
patients with Parkinson’s disease have increased the 
incidence of melanoma in these patients several 
times. 
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